4-{[(4-trifluorophenylmethyl)hydrazono]methyl}pyridine | 518342-41-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[(4-trifluorophenylmethyl)hydrazono]methyl}pyridine
• 英文别名: 4-(((4-trifluorophenyl)hydrazono)methyl)pyridine；N-(pyridin-4-ylmethylideneamino)-4-(trifluoromethyl)aniline
• CAS: 518342-41-1
• 化学式: C₁₃H₁₀F₃N₃
• 分子量: 265.238
• InChiKey: PEPGFJAXLRKUCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-{[(4-trifluorophenylmethyl)hydrazono]methyl}pyridine 在 N-氯代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以74%的产率得到N-(4-trifluoromethylphenyl)pyridine-4-carbohydrazonoyl chloride
  参考文献：
  名称：

  Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases

  摘要：

  In the course of searching for new p38 alpha MAP kinase inhibitors, we found that the regioisomeric switch from 3-(4-fluorophenyl)-4-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine to 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine led to an almost complete loss of p38a inhibition, but they showed activity against important cancer kinases. Among the tested derivatives, 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-S-amine (6a) exhibited the best activity, with IC50 in the nanomolar range against Src, B-Raf wt, B-Raf V600E, EGFRs, and VEGFR-2, making it a good lead for novel anticancer programs.

  DOI：

  10.1021/jm201391u
• 作为产物：
  描述：

  4-吡啶甲醛 、 4-(三氟甲基)苯肼 以 乙醇 为溶剂， 以73%的产率得到4-{[(4-trifluorophenylmethyl)hydrazono]methyl}pyridine
  参考文献：
  名称：

  Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases

  摘要：

  In the course of searching for new p38 alpha MAP kinase inhibitors, we found that the regioisomeric switch from 3-(4-fluorophenyl)-4-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine to 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine led to an almost complete loss of p38a inhibition, but they showed activity against important cancer kinases. Among the tested derivatives, 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-S-amine (6a) exhibited the best activity, with IC50 in the nanomolar range against Src, B-Raf wt, B-Raf V600E, EGFRs, and VEGFR-2, making it a good lead for novel anticancer programs.

  DOI：

  10.1021/jm201391u

文献信息

• [EN] PYRIDINYLPYRAZOLES FOR USE AS KINASE MODULATORS FOR THE TREATMENT OF CANCER<br/>[FR] PYRIDINYLPYRAZOLES DESTINÉS À ÊTRE UTILISÉS COMME MODULATEURS DE KINASE DANS LE TRAITEMENT DU CANCER
  申请人：SYNOVO GMBH

  公开号：WO2013046041A1

  公开（公告）日：2013-04-04

  Compounds of the substituted pyrazole class of Formula (I) as treatments for cancer are reported. A method of treating cancer in which a compound that inhibits the activity of receptor kinases is described. Said method is effective and can be provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.

  报道了公式（I）的取代吡唑类化合物作为治疗癌症的方法。描述了一种抑制受体激酶活性的化合物治疗癌症的方法。该方法是有效的，并可在标准治疗，特别是使用细胞毒性药物的化疗和其他形式的免疫疗法，包括治疗性疫苗的基础上提供。
• Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases
  作者：Bassam Abu Thaher、Martina Arnsmann、Frank Totzke、Jan E. Ehlert、Michael H. G. Kubbutat、Christoph Schächtele、Markus O. Zimmermann、Pierre Koch、Frank M. Boeckler、Stefan A. Laufer

  DOI：10.1021/jm201391u

  日期：2012.1.26

  In the course of searching for new p38 alpha MAP kinase inhibitors, we found that the regioisomeric switch from 3-(4-fluorophenyl)-4-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine to 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine led to an almost complete loss of p38a inhibition, but they showed activity against important cancer kinases. Among the tested derivatives, 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-S-amine (6a) exhibited the best activity, with IC50 in the nanomolar range against Src, B-Raf wt, B-Raf V600E, EGFRs, and VEGFR-2, making it a good lead for novel anticancer programs.